Focused On-demand Library for Carboxypeptidase B2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96IY4

UPID:

CBPB2_HUMAN

Alternative names:

Carboxypeptidase U; Plasma carboxypeptidase B; Thrombin-activable fibrinolysis inhibitor

Alternative UPACC:

Q96IY4; A8K464; Q15114; Q5T9K1; Q5T9K2; Q9P2Y6

Background:

Carboxypeptidase B2, known alternatively as Carboxypeptidase U, Plasma carboxypeptidase B, and Thrombin-activable fibrinolysis inhibitor, plays a crucial role in the regulation of biological activities by cleaving C-terminal arginine or lysine residues from active peptides. It is instrumental in modulating the activities of kinins and anaphylatoxins in the circulation, and it significantly impacts fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin.

Therapeutic significance:

Understanding the role of Carboxypeptidase B2 could open doors to potential therapeutic strategies.